Pediatrix Medical Group, Inc.

Pediatrix Medical Group, Inc. (MD) Market Cap

Pediatrix Medical Group, Inc. has a market capitalization of $2.18B.

Price: $26.51

▲ 0.03 (0.11%)

Market Cap: 2.18B

NYSE ¡ time unavailable

CEO: Mark S. Ordan

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 1995-09-20

Website: https://www.pediatrix.com

Pediatrix Medical Group, Inc. (MD) - Company Information

Market Cap: 2.18B|Sector: Healthcare

Company Profile

Pediatrix Medical Group, Inc. delivers specialized medical services for newborns, expectant mothers, and pediatric patients across the United States and Puerto Rico. The company offers crucial neonatal care to critically ill or prematurely born infants within hospital units, staffed by expert neonatal subspecialists and advanced practice clinicians. For pregnant individuals and their developing babies, Pediatrix provides comprehensive maternal-fetal medicine services in both clinical and inpatient settings, involving specialists such as maternal-fetal medicine physicians, obstetricians, and genetic counselors. Furthermore, the group delivers pediatric cardiology services, addressing both congenital and acquired heart conditions in patients ranging from the fetal stage through adulthood, under the care of dedicated pediatric cardiologists. Beyond these core areas, Pediatrix extends its expertise to various other pediatric subspecialties, including those requiring intensivists, surgeons, and ophthalmologists, and supplies vital support to hospital departments like emergency rooms and labor and delivery units. Established in 1979 in Sunrise, Florida, and formerly known as MEDNAX, Inc. until its renaming in July 2022, the company managed a network of approximately 2,700 physicians as of February 2022.

Analyst Sentiment

45%
Hold

From 7 Active Polls

1Y Forecast: $24.60

▼ -7.2% Potential Upside

Consensus Target Metrics

Low Bound

$19

Median

$25

High Bound

$28

Average

$25

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$24.60
▼ -7.20% Upside
Low Target
$19.00
-28% Risk
Median Target
$25.00
-6% Mid
High Target
$28.00
6% Max
Consensus
Hold
14 / 33 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)2,1771,7771,8061,4301,2461,2431,127972592
Enterprise Value ($M)2,6012,2012,0911,7321,6711,8001,5591,5521,271
Price to Earnings Ratio (P/E)12.8714.8513.374.937.9715.099.3712.60-0.97
Price/Earnings-to-Growth Ratio (PEG)——73.540.963.49——9.26-0.52
Price to Sales Ratio (P/S)1.133.733.662.902.662.712.241.901.17
Price to Book Ratio (P/B)2.512.022.091.611.491.581.471.330.84
Price to Free Cash Flow Ratio (P/FCF)9.16-13.0916.5910.849.40-10.298.6911.375.93
Enterprise Value to Sales (EV/Sales)—4.624.233.513.563.933.103.042.52
Enterprise Value to EBITDA (EV/EBITDA)9.3241.3534.8617.9724.0842.2731.2337.30-8.55
Debt to Equity Ratio1.520.720.760.720.780.830.870.930.99

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 PEDIATRIX MEDICAL GROUP INC (MD) — Investment Overview

🧩 Business Model Overview

Pediatrix provides specialized physician services through long-duration coverage arrangements with hospitals and health systems, primarily in high-acuity settings such as neonatal intensive care units (NICUs), maternal-fetal medicine, and other pediatric specialties. The business model is built around staffing and clinical operations: recruiting and credentialing specialty physicians, coordinating care workflows with hospital clinicians, and managing billing and compliance for professional services.

Because services are delivered on-site and require ongoing staffing continuity, the customer “switch” is costly for hospitals. Contract duration, credentialing, care-team continuity, and operational handoffs create stickiness and support recurring utilization across patient volumes.

💰 Revenue Streams & Monetisation Model

Revenue is primarily generated from professional billing tied to patient encounters and coverage responsibilities under negotiated payer and contract terms. The monetisation model is dominated by:

  • Recurring coverage revenue from contracted hospital coverage (ongoing staffing needs drive recurring recognition).
  • Encounter-driven professional fees that scale with NICU and high-risk obstetric volumes.
  • Contractual reimbursement dynamics shaped by payer mix (Medicare, Medicaid, commercial), medical necessity documentation, and coding accuracy.

Key margin drivers include physician staffing efficiency (mix of employed vs. contracted physicians, utilization within covered sites), contract structure (rates and terms), payer reimbursement intensity, and the effectiveness of revenue cycle operations (coding, denial management, and collections discipline).

🧠 Competitive Advantages & Market Positioning

Pediatrix’s moat is best understood as high switching costs plus integrated clinical ecosystems within hospital networks—built from credentialing, care-team continuity, and operational muscle.

  • Switching costs for hospitals: Replacing a specialty group requires re-credentialing, rebuilding care workflows, reassigning escalation pathways, and managing patient handoffs—particularly in NICU and maternal-fetal medicine where continuity and protocols matter.
  • Integrated ecosystem: Coordinated specialty care with hospital staff, standardized clinical processes, and operational systems for compliance and revenue cycle management raise the difficulty of replication by smaller or less scaled operators.
  • High barriers to entry: Recruiting and retaining appropriately trained sub-specialists, maintaining board certification and credentialing readiness, and delivering consistent outcomes across multiple sites are non-trivial—especially when coverage requires round-the-clock readiness in high-acuity environments.

Competitive benchmarking (industry peers):

  • Envision Healthcare: More diversified across hospital-based physician services. Pediatrix’s emphasis is narrower and centered on perinatal and pediatric-related specialties with high acuity.
  • TeamHealth (hospital-based specialty services): Broad footprint with strengths in emergency and other coverage lines. Pediatrix’s differentiation lies in specialty clinical focus and depth in neonatal/perinatal care models.
  • Academic medical centers / internally staffed hospital programs: Compete through institutional affiliation and integrated care systems. Pediatrix’s advantage is scale across multiple hospitals and operational specialization in physician coverage rather than solely institutional employment models.

🚀 Multi-Year Growth Drivers

Growth over a 5–10 year horizon is supported by structural demand and capacity constraints rather than purely volume expansion. Core drivers include:

  • Specialty care intensity: Ongoing medical complexity in neonatal and maternal-fetal care increases the need for experienced, protocol-driven specialty coverage.
  • Physician workforce scarcity: Broad specialty shortages encourage hospitals to outsource or partner with scalable physician groups that can recruit, credential, and operationalize coverage.
  • Shift toward outsourced specialty coverage: Health systems often prefer contracted specialty operators to manage labor constraints, scheduling, and compliance overhead.
  • Contract expansion and site additions: Strong performance and operational reliability can support incremental coverage expansion within existing hospital relationships.

⚠ Risk Factors to Monitor

  • Reimbursement pressure: Changes in Medicare/Medicaid payment rules and commercial payer contract dynamics can compress rates and impact utilization economics.
  • Regulatory and billing scrutiny: Professional services are exposed to coding, documentation, and compliance expectations; adverse findings can increase costs and reduce revenue capture.
  • Contract concentration and renewal risk: A meaningful portion of results can depend on maintaining and renegotiating hospital coverage agreements.
  • Physician recruiting and retention: Specialty labor scarcity can raise staffing costs or reduce coverage flexibility, impacting margins and service levels.
  • Litigation and malpractice: High-acuity specialties face legal risk that can affect operating costs and insurability.

📊 Valuation & Market View

Specialty physician services are typically valued using EV/EBITDA and P/S, with investors emphasizing earnings quality, contract durability, and reimbursement resilience. The key valuation drivers include:

  • Contract stability and expected renewal cadence.
  • Operating leverage from staffing utilization and revenue cycle performance.
  • Margin sustainability, reflecting reimbursement mix and staffing economics.
  • Balance sheet and cash conversion, particularly working capital behavior tied to payer reimbursement timing.

Because these businesses are operationally intensive and reimbursement-driven, valuation dispersion often reflects differences in contract quality, payer mix, and compliance maturity.

🔍 Investment Takeaway

Pediatrix’s long-term thesis rests on a structural advantage in delivering high-acuity specialty care through scalable, hospital-embedded operations. The principal moat is switching costs for health systems combined with integrated clinical and operational ecosystems that are difficult for new entrants to replicate quickly. Sustainable growth should be supported by specialty demand, ongoing healthcare labor constraints, and continued reliance on contracted specialty coverage—tempered by reimbursement, regulatory, and staffing risks that require disciplined execution.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for MD.

defenseworld.net•2026-07-21

Allspring Global Investments Holdings LLC Acquires 335,733 Shares of Pediatrix Medical Group, Inc. $MD

Allspring Global Investments Holdings LLC increased its holdings in Pediatrix Medical Group, Inc. (NYSE: MD) by 52.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 975,133 shares of the company's stock after acquiring an additional 335,733 shares during the period.

defenseworld.net•2026-07-17

Pediatrix Medical Group, Inc. (NYSE:MD) Receives Consensus Rating of “Hold” from Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE: MD - Get Free Report) have received a consensus recommendation of "Hold" from the six brokerages that are currently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year

zacks.com•2026-07-16

Pediatrix Medical Group (MD) Soars 7.3%: Is Further Upside Left in the Stock?

Pediatrix Medical Group (MD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

zacks.com•2026-07-15

Why Pediatrix Medical Group (MD) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

businesswire.com•2026-07-15

Pediatrix Medical Group Provides Second Quarter Update

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)---- $MD--Pediatrix Medical Group, Inc. (NYSE: MD) (“Pediatrix” or “the Company”), a leading provider of physician services, today provided an update on its second quarter 2026 business trends. In response to recent reports from other healthcare market participants regarding shifting utilization and reimbursement trends, the Company confirms that its payor mix for the second quarter remained stable and unchanged relative to recent historical trends and the Company'.

zacks.com•2026-07-14

Why Pediatrix Medical Group (MD) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

zacks.com•2026-06-26

Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock: Should You Buy?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

zacks.com•2026-06-23

Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

businesswire.com•2026-06-23

New CV APP Compensation and Utilization Survey Report Highlights Growing APP Contributions, Prompting Focus on Support and Compensation

JACKSONVILLE BEACH, Fla.--(BUSINESS WIRE)--MedAxiom, the premier source for cardiovascular organizational performance solutions, has released the 2025 Cardiovascular Advanced Practice Provider (APP) Compensation and Utilization Report, which includes data from more than 100 provider organizations. The report features a foreword from Jerry Blackwell, MD, MBA, FACC, president and CEO of MedAxiom, highlighting APP contributions to productivity, workflow, access, and patient satisfaction, enabling.

globenewswire.com•2026-06-22

Maryland Public Television earns 20 regional EmmyÂŽ Awards

OWINGS MILLS, MD, June 22, 2026 (GLOBE NEWSWIRE) -- The National Capital Chesapeake Bay Chapter of the National Academy of Television Arts & Sciences presented Maryland Public Television with 20 Emmys during its 68th Capital EmmyŽ Awards ceremony at the Bethesda North Marriott Hotel and Conference Center on Saturday, June 20. NATAS-NCCB comprises television industry professionals dedicated to fostering and recognizing outstanding achievements in television production in Maryland, Virginia, and Washington, D.C.

globenewswire.com•2026-06-17

New Anglia University Responds to Rising Competition for Medical School Places in the UK

George Hill, Anguilla, 17 June 2026 -- As competition for medical school places in the United Kingdom reaches unprecedented levels, New Anglia University is providing aspiring doctors with an alternative pathway to medical education through its UK-aligned Doctor of Medicine (MD) programme, which combines an integrated curriculum with extensive NHS-based clinical rotations. The University's approach comes at a time when demand for medical school places continues to significantly exceed available capacity, leaving thousands of qualified applicants without a place each year despite strong academic credentials and a clear commitment to pursuing a career in medicine.

businesswire.com•2026-06-11

Onera Will Showcase Its Onera hPSGÂŽ Solution at the SLEEP 2026 Conference June 14-17, 2026 in Baltimore, MD, USA.

EINDHOVEN, Netherlands--(BUSINESS WIRE)-- #MedicalDevice--Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSGÂŽ solution, will be prominently featured in multiple scientific presentations at the forthcoming SLEEP 2026 conference. The medtech company will showcase this innovative solution at booth #600 during the largest annual sleep medicine conference, which brings together leading experts and innovators in the field. Furthermore, in.

zacks.com•2026-06-10

Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

globenewswire.com•2026-06-04

Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors

BRISANE, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest” or “Tempest Therapeutics”) today announced the appointment of two independent directors, Drake Richey and John Yee, MD, MPH to its Board of Directors (the “Board”), effective [June 4, 2026]. Mr. Richey and Dr. Yee collectively bring decades of experience in corporate finance and therapeutic product development to the Board.

zacks.com•2026-06-04

Why Is Pediatrix Medical Group (MD) Down 1.7% Since Last Earnings Report?

Pediatrix Medical Group (MD) reported earnings 30 days ago. What's next for the stock?

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"MD reported Q1 2026 revenue of $476.2M and net income of $29.6M (EPS $0.36). Compared with Q1 2025, revenue rose to 476.2M from 458.4M (+3.9% YoY) and net income increased to 29.6M from 20.7M (+42.7% YoY). Sequentially, revenue declined slightly from $493.8M in Q4 2025 (-3.6% QoQ), while net income eased from $33.7M (-12.2% QoQ). Profitability improved versus last year: the net margin expanded from 4.5% in Q1 2025 to 6.2% in Q1 2026 (+1.7pp), though it contracted versus Q4 2025 (6.8%). Cash flow quality weakened in the quarter: operating cash flow was -$129.5M and free cash flow -$135.7M, indicating significant working-capital/other cash dynamics versus the prior quarter’s positive operating cash flow (+$114.1M). Balance sheet resilience remains solid with total assets of $2.07B and equity of $878.6M. Leverage is moderate (net debt ~$423.9M; debt-to-equity ~0.72), with liquidity improved versus Q4 2025 (cash & ST investments $329.0M vs $499.7M, though equity stayed stable). Shareholder returns look strong: the stock is up 75.6% over 1 year (well above the >20% momentum threshold), and while there is no dividend, management continued buybacks (Q1 repurchase $21.5M)."

Revenue Growth

Neutral

Revenue +3.9% YoY in Q1 2026 ($476.2M vs $458.4M) but -3.6% QoQ ($476.2M vs $493.8M), signaling a mild deceleration sequentially.

Profitability

Good

Net margin expanded to 6.2% in Q1 2026 from 4.5% in Q1 2025 (+1.7pp). Net income +42.7% YoY and EPS $0.36 vs $0.24 YoY, though net margin contracted vs Q4 2025 (6.8%).

Cash Flow Quality

Neutral

Operating cash flow was -$129.5M and free cash flow -$135.7M in Q1 2026, a sharp deterioration vs Q4 2025 (+$114.1M operating cash flow). Indicates lower near-term cash conversion.

Leverage & Balance Sheet

Positive

Equity is stable at $878.6M and total assets are $2.07B. Net debt is ~$423.9M with debt-to-equity ~0.72, suggesting manageable leverage and adequate balance-sheet resilience.

Shareholder Returns

Strong

Total return tailwind is strong: price is up +75.6% over 1 year. No dividend, but buybacks continued (repurchases of ~$21.5M in Q1 2026), supporting capital appreciation.

Analyst Sentiment & Valuation

Positive

Current price $23.07 vs consensus target ~$22.25 implies modest upside/downside near-term. The valuation multiples appear reasonable on earnings (P/E ~15) but cash-flow multiples are distorted by weak Q1 cash generation.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Pediatrix reported strong Q1 2026 results with adjusted EBITDA of $58 million and reaffirmed full-year adjusted EBITDA guidance of $280–$300 million. The key driver was pricing up 4%, supported by RCM cash collections, contract administrative fees, favorable payer mix, and higher neonatology acuity. Same-unit growth just under 3% offset modest volume softness (NICU days down ~1%). The company highlighted improved collections (DSO 42.5 days, down over 5 days YoY), while acknowledging that the RCM component should fade in the second half as it laps (management quantified ~25% of Q1 pricing from cash collections). Despite concerns about hospital system volume pressures and an uncertain tax subsidy lapse, management is comfortable not assuming a headwind and expects the rest of the year to be fairly ratable. Q&A focus centered on quantifying pricing components, admin fee dynamics, and whether volume declines are actually resuming—management said no.

AI IconGrowth Catalysts

  • Pricing up 4% in Q1, driven by stronger RCM cash collections, contract administrative fees, favorable payer mix, and higher neonatology acuity
  • Same unit growth just under 3% supporting revenue increase despite modest volume declines
  • Improved RCM cash collections reflected in DSO down to 42.5 days (down over 5 days YoY)

Business Development

  • Named hires joining Pediatrix: Dr. Jim Barry (Chief Clinical Quality and Transformation Officer) from University of Colorado Health System; Dr. Jochen Profit (Chief Quality Adviser) from Stanford Medicine
  • Recent acquisitions contributing net non-same unit activity of about $6 million; acquisitions reportedly performing better than initial projections

AI IconFinancial Highlights

  • Adjusted EBITDA: $58 million in Q1; reiterated full-year adjusted EBITDA outlook of $280 million to $300 million
  • Revenue growth driven by same unit growth just under 3% and net non-same unit activity about $6 million, partially offset by portfolio restructuring revenue decreases
  • Pricing growth of 4% in Q1; management indicated pricing should tick down in H2 (RCM cash collection tail-off) while maintaining flat full-year pricing outlook
  • Volume: NICU days down about 1% in Q1; company stated recent volume declines are not continuing into latest results (no different forecast)
  • Expenses: practice level SW&B up $9 million YoY (primarily clinical salary expense from same unit growth); G&A slightly up due to modest salary/incentive increases; D&A slightly up from higher same unit amortization and acquisition D&A
  • Cash flow: used $130 million operating cash flow in Q1 vs $116 million prior year; increase due to decreased cash from AP/accrued expenses tied to incentive comp payments and lower AR cash collections (offset by higher earnings)
  • Capital structure: repurchased $21 million of stock (1 million shares), ended Q1 with cash just over $200 million and net debt just over $385 million; net leverage just over 1.3x using midpoint of updated 2026 outlook

AI IconCapital Funding

  • Share repurchase: $21 million deployed in Q1 to buy ~1 million shares
  • Cash: just over $200 million at quarter end
  • Net debt: just over $385 million at quarter end
  • Net leverage: just over 1.3x using midpoint of updated adjusted EBITDA outlook for 2026

AI IconStrategy & Ops

  • Expanded care quality leadership and commercialization through clinical quality/AI transformation hires (Dr. Jim Barry; Dr. Jochen Profit)
  • Compensation/ownership alignment: rolled out share price-based awards in Q4 last year and Q1 this year; welcomed 45 clinician leaders to inaugural Pediatrix partner class

AI IconMarket Outlook

  • Reaffirmed full-year 2026 adjusted EBITDA outlook of $280 million to $300 million
  • Expected remaining 3 quarters to be fairly ratable (Q1 about 20% of annual expected range)
  • Pricing outlook maintained as flat for the year despite expectation pricing headwinds in H2 from RCM cash collection lapping/tail-off

AI IconRisks & Headwinds

  • Potential tax subsidy lapse headwind discussed; management comfortable with decision to not include a headwind estimate but acknowledged major hospital systems have seen declines and that patient volume/revenue decline could emerge
  • Volume weakness risk: NICU days down about 1% in Q1; management said it did not continue in most recent results but cannot identify root cause of prior declines
  • Hospital environment pressure risk: contract administrative fee support is viewed as potentially less certain; company indicated hospitals face tougher conditions making negotiations harder
  • RCM cash collection timing risk: management expects RCM-driven pricing to tail off after strong first half; first half strength expected to lap in second half

Q&A: Analyst Interest

  • RCM cash collections vs pricing run-rate: Management quantified that about 25% of Q1 pricing came from cash collections, expecting RCM strength to tail off in the back half as it laps. They maintained that overall pricing can stay flat despite this fading driver and reiterated no sign of weakness.
  • Contract administrative fees visibility and behavior: Management stated contract revenue strength continues but negotiations are getting tougher; admin fees have historically comprised 10% to 20% of pricing increases and were ~20% higher end in Q1. They declined specific book mix/pace details beyond noting thousands of contracts vary and no disclosed trends.
  • Volume trend outlook for NICU days: Analysts asked whether the prior two quarters’ declining NICU days trend would persist and what could improve it. Management responded that in recent results the decline was not continuing, so they do not have a different forecast, citing no observed ongoing trend to drive change.

Sentiment: MIXED

Note: This summary was synthesized by AI from the MD Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for MD.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (MD)

© 2026 Stock Market Info — Pediatrix Medical Group, Inc. (MD) Financial Profile